Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy – A Piece of a Much Larger Puzzle

Author(s): Agnieszka Dębska-Kozłowska, Izabela Warchoł, Marcin Książczyk* and Andrzej Lubiński

Volume 19, Issue 4, 2021

Published on: 14 April, 2020

Page: [403 - 410] Pages: 8

DOI: 10.2174/1570161118666200414103432

Price: $65

Abstract

Background: Although cardiac resynchronisation therapy (CRT) is an important player in the treatment of patients with heart failure (HF), the proportion of CRT patients with no improvement in either echocardiographic or clinical parameters remains consistently high and accounts for about 30% despite meeting CRT implantation criteria. Furthermore, in patients suffering from HF, renal dysfunction accounts for as many as 30-60%. Accordingly, CRT may improve renal function inducing a systemic haemodynamic benefit leading to increased renal blood flow.

Objectives: The aim of the present study was to evaluate the importance of renal function in response to resynchronisation therapy during a 12-month follow-up period.

Materials and Methods: The study consisted of 46 HF patients qualified for implantation of cardiac resynchronisation therapy defibrillator (CRT-D). A CRT responder is defined as a person without chronic HF exacerbations during observation whose physical efficiency has improved owing to the New York Heart Association (NYHA) class improvement ≥1.

Results: A statistically significant difference was noted between responders and non-responders regarding creatinine level at the 3rd month (p=0.04) and, particularly, at the 12th month (p=0.02) of follow-up (100±23 vs 139±78 μmol/l). Moreover, there was a remarkable difference between both study groups with regard to GFR CKD-EPI (glomerular filtration rate (GFR) assessed using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula) at the 6th (p=0.03) and 12th month (p=0.01) of follow-up. The reference values for initial creatinine concentrations (101 μmol/l) as well as GFR CKDEPI (63 ml/min/1.73m2) were empirically evaluated to predict favourable therapeutic CRT response.

Conclusion: Predictive value of GFR CKD-EPI and creatinine concentration for a positive response to CRT was found relevant.

Keywords: Cardiac resynchronisation therapy, chronic heart failure, chronic kidney disease, estimated glomerular filtration rate, CRT responders, CRT non-responders.

« Previous Next »
Graphical Abstract

[1]
Daubert JC, Saxon L, Adamson PB, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace 2012; 14(9): 1236-86.
[http://dx.doi.org/10.1093/europace/eus222] [PMID: 22930717]
[2]
Poulidakis E, Aggeli C, Sideris S, et al. Echocardiography for prediction of 6-month and late response to cardiac resynchronization therapy: implementation of stress echocardiography and comparative assessment along with widely used dyssynchrony indices. Int J Cardiovasc Imaging 2019; 35(2): 285-94.
[http://dx.doi.org/10.1007/s10554-018-01520-6] [PMID: 30623352]
[3]
Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: the magnitude of the problem and the issues. Circ J 2011; 75(3): 521-7.
[http://dx.doi.org/10.1253/circj.CJ-10-1268] [PMID: 21325727]
[4]
Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3(3): 315-22.
[http://dx.doi.org/10.1016/S1388-9842(00)00141-0] [PMID: 11378002]
[5]
Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13(6): 422-30.
[http://dx.doi.org/10.1016/j.cardfail.2007.03.011] [PMID: 17675055]
[6]
Mullens W, Verga T, Grimm RA, Starling RC, Wilkoff BL, Tang WHW. Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol 2009; 53(7): 600-7.
[http://dx.doi.org/10.1016/j.jacc.2008.08.079] [PMID: 19215835]
[7]
Fornwalt BK, Sprague WW. BeDell P, etal Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 2010; 121(18): 1985-91.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.910778] [PMID: 20421518]
[8]
Gold MR, Thébault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study. Circulation 2012; 126(7): 822-9.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.097709] [PMID: 22781424]
[9]
Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010; 55(4): 622-7.
[http://dx.doi.org/10.1053/j.ajkd.2010.02.337] [PMID: 20338463]
[10]
KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1.
[11]
Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American heart association electrocardiography and arrhythmias committee, council on clinical cardiology; the American college of cardiology foundation; and the heart rhythm society. J Am Coll Cardiol 2009; 53(11): 976-81.
[http://dx.doi.org/10.1016/j.jacc.2008.12.013] [PMID: 19281930]
[12]
Kpaeyeh JA Jr, Divoky L, Hyer JM, et al. Impact of renal function on survival after cardiac resynchronization therapy. Am J Cardiol 2017; 120(2): 262-6.
[http://dx.doi.org/10.1016/j.amjcard.2017.04.017] [PMID: 28545627]
[13]
Linhart C, Ulrich C, Greinert D, et al. Systemic inflammation in acute cardiorenal syndrome: an observational pilot study. ESC Heart Fail 2018; 5(5): 920-30.
[http://dx.doi.org/10.1002/ehf2.12327] [PMID: 30015388]
[14]
Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronisation therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50.
[15]
Van Bommel RJ, Mollema SA, Borleffs CJ, et al. Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2011; 57(5): 549-55.
[http://dx.doi.org/10.1016/j.jacc.2010.06.060] [PMID: 21272745]
[16]
Nauffal V, Tanawuttiwat T, Zhang Y, et al. Predictors of mortality, LVAD implant, or heart transplant in primary prevention cardiac resynchronization therapy recipients: The HF-CRT score. Heart Rhythm 2015; 12(12): 2387-94.
[http://dx.doi.org/10.1016/j.hrthm.2015.07.026] [PMID: 26190316]
[17]
Shalaby A, El-Saed A, Voigt A, Albany C, Saba S. Elevated serum creatinine at baseline predicts poor outcome in patients receiving cardiac resynchronization therapy. Pacing Clin Electrophysiol 2008; 31(5): 575-9.
[http://dx.doi.org/10.1111/j.1540-8159.2008.01043.x] [PMID: 18439171]
[18]
Cai C, Hua W, Ding L, et al. Association of renal function with cardiac reverse remodeling and long-term outcome in heart failure patients following cardiac resynchronization therapy. Chin Med J (Engl) 2014; 127(23): 4036-42.
[PMID: 25430445]
[19]
Lin G, Gersh BJ, Greene EL, Redfield MM, Hayes DL, Brady PA. Renal function and mortality following cardiac resynchronization therapy. Eur Heart J 2011; 32(2): 184-90.
[http://dx.doi.org/10.1093/eurheartj/ehq403] [PMID: 21068051]
[20]
Hosoda J, Ishikawa T, Matsushita K, et al. Impact of renal insufficiency on long-term clinical outcome in patients with heart failure treated by cardiac resynchronization therapy. J Cardiol 2012; 60(4): 301-5.
[http://dx.doi.org/10.1016/j.jjcc.2012.06.001] [PMID: 22763383]
[21]
Bogdan S, Klempfner R, Sabbag A, et al. Functional response to cardiac resynchronization therapy in patients with renal dysfunction and subsequent long-term mortality. J Cardiovasc Electrophysiol 2014; 25(11): 1188-95.
[http://dx.doi.org/10.1111/jce.12463] [PMID: 24891182]
[22]
Garg N, Thomas G, Jackson G, et al. Cardiac resynchronization therapy in CKD: a systematic review. Clin J Am Soc Nephrol 2013; 8(8): 1293-303.
[http://dx.doi.org/10.2215/CJN.00750113] [PMID: 23660183]
[23]
Boerrigter G, Costello-Boerrigter LC, Abraham WT, et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail 2008; 14(7): 539-46.
[http://dx.doi.org/10.1016/j.cardfail.2008.03.009] [PMID: 18722318]
[24]
Adelstein EC, Shalaby A, Saba S. Response to cardiac resynchronization therapy in patients with heart failure and renal insufficiency. Pacing Clin Electrophysiol 2010; 33(7): 850-9.
[http://dx.doi.org/10.1111/j.1540-8159.2010.02705.x] [PMID: 20202138]
[25]
Schaer BA, Hitz L, Sticherling C, et al. Changes in renal function over time in patients with cardiac resynchronisation therapy. Swiss Med Wkly 2013; 143: 13863.
[http://dx.doi.org/10.4414/smw.2013.13863] [PMID: 24163096]
[26]
Moreira RI, Cunha PS, Rio P, et al. Response and outcomes of cardiac resynchronization therapy in patients with renal dysfunction. J Interv Card Electrophysiol 2018; 51(3): 237-44.
[http://dx.doi.org/10.1007/s10840-018-0330-6] [PMID: 29460235]
[27]
de Boer RA, De Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure. Eur J Heart Fail 2019; 21(3): 272-85.
[http://dx.doi.org/10.1002/ejhf.1406] [PMID: 30714667]
[28]
Massoullié G, Sapin V, Ploux S, et al. Low fibrosis biomarker levels predict cardiac resynchronization therapy response. Sci Rep 2019; 9(1): 6103.
[http://dx.doi.org/10.1038/s41598-019-42468-4] [PMID: 30988339]
[29]
de Franciscis S, Metzinger L, Serra R. Roles and clinical applications of biomarkers in cardiovascular disease. BioMed Res Int 2016; 20168982796
[PMID: 27478841]

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy